🟢 Edesa Biotech is trading 7.7% up in after-hours trading without a clearly identified catalyst

Edesa Biotech is trading at $6.15, up 7.71% after-hours on August 18, 2026, without a clearly identified company-specific catalyst.

• The August 13 earnings release reported a $5.4 million quarterly net loss and said recruitment for the Phase 2 EB06 vitiligo study should begin in the coming weeks.
• It contains no August 18 announcement or explanation for the move; broader markets declined, so the gain does not clearly track overall sentiment.